Neoadjuvant chemoradiotherapy followed by surgery demonstrates enhanced overall survival (OS) rates compared to upfront surgery and neoadjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer. This approach also increases margin-negative resection rates and pathological negative lymph node rates. However, it carries a higher risk of grade 3 or higher treatment-related adverse events, particularly in locally advanced cases. These findings suggest that neoadjuvant chemoradiotherapy followed by surgery is the preferred treatment for resectable and borderline pancreatic cancer. Future research should focus on optimizing this regimen to balance improved OS with reduced adverse events in these patient populations.
Comparative Study by He J, Lv N (…) Wu C et 3 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.